Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04679311 · ClinicalTrials.gov registry record · Phase 2
Treatment of Angiotensin Converting Enzyme Inhibitor-induced Angioedema
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04679311 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 2 participants.
The verdict
NCT04679311, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Angiotensin Converting Enzyme (ACE) inhibitors are among the most important and widely prescribed drugs. They reduce the morbidity and mortality associated with high blood pressure, heart disease, and kidney disease. Unfortunately, their use carries the risk of causing life-threatening airway swelling in some patients. There is currently no treatment for this condition. A novel treatment approach that may reduce or completely reverse the swelling will be tested.
Interventions
- OTHER Normal Saline
- BIOLOGICAL High ACE Activity Fresh Frozen Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04679311
The ClinicalTrials.gov registry entry for NCT04679311 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT04679311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04679311 about?
NCT04679311 is a clinical study titled "Treatment of Angiotensin Converting Enzyme Inhibitor-induced Angioedema". Angiotensin Converting Enzyme (ACE) inhibitors are among the most important and widely prescribed drugs. They reduce the morbidity and mortality associated with high blood pressure, heart disease, and kidney disease. Unfortunately, their use carries the risk of causing life-threatening airway swelli...
What is the current status of trial NCT04679311?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-12-22. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04679311?
The interventions under investigation include: Normal Saline (OTHER), High ACE Activity Fresh Frozen Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04679311?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.